Get the Stockscreener App
13.00
6.21%
0.76
Obsidian Therapeutics, Inc. Common Stock stock is traded at $13.00, with a volume of 532.19K.
It is up +6.21% in the last 24 hours and down -30.41% over the past month.
See More
Previous Close:
$12.24
Open:
$12.25
24h Volume:
532.19K
Relative Volume:
1.31
Market Cap:
$803.05M
Revenue:
Net Income/Loss:
P/E Ratio:
-
EPS:
-
Net Cash Flow:
1W Performance:
-4.34%
1M Performance:
-30.41%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$12.07
$14.41
52-Week Range:
$12.07
$49.97
Obsidian Therapeutics, Inc. Common Stock Stock (OBX) Company Profile
Name
Obsidian Therapeutics, Inc. Common Stock
Sector
Industry
Phone
-
Address
-
Compare OBX vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OBX
Obsidian Therapeutics, Inc. Common Stock
|
13.00 | 803.05M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Obsidian Therapeutics, Inc. Common Stock Stock (OBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-26 | Initiated | Leerink Partners | Outperform |
| Sep-09-26 | Initiated | William Blair | Outperform |
| Aug-06-26 | Initiated | TD Cowen | Buy |
| Aug-05-26 | Initiated | Piper Sandler | Overweight |
Obsidian Therapeutics, Inc. Common Stock Stock (OBX) Latest News
Paradigm BioCapital Reports 6.6% Ownership Stake in Obsidian Therapeutics - Kalkine Media
A passive investor reports 4.1M shares of Obsidian Therapeutics (OBX). - Stock Titan
Iovance Biotherapeutics (NasdaqGM:IOVA) Stock Forecast & Analyst Predictions - Simply Wall Street
Obsidian Therapeutics, Inc.(NasdaqCM: OBX) added to S&P TMI Index - marketscreener.com
A booming business on Wall Street would love more biotechs to quietly die - BioPharma Dive
William Blair initiates Obsidian Therapeutics stock with outperform rating - Investing.com
Obsidian TherapeuticsFiles Prospectus Relates To Resale Of Up To 29,164,045 Shares Of Common Stock By Selling Stockholders- SEC Filing - TradingView
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement - Yahoo Finance
Obsidian Therapeutics (OBX) director Heidi Hagen reports 517,500 option shares - Stock Titan
Tenax Therapeutics (NASDAQ:TENX) Drops 85% as Phase 3 LEVEL Study Fails to Meet Main Endpoints - TechStock²
symbol__ Stock Quote Price and Forecast - CNN
Obsidian Therapeutics (OBX) 10K Form and Latest SEC Filings 2026 - MarketBeat
Octagon Capital Advisors2026 Investor Profile, Portfolio, Team & Investment Trends - Tracxn
OBX News Today | Why did Obsidian Therapeutics stock go up today? $OBX - MarketBeat
Obsidian Therapeutics (OBX) Stock Chart and Price History 2026 $OBX - marketbeat.com
Obsidian Therapeutics (OBX) Stock Price, News & Analysis $OBX - MarketBeat
Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma - Business Wire
TCGX Acquisition Corp. (TCGX) stock price, news, quote and history - Yahoo Finance UK
Obsidian Therapeutics, Inc. (OBX) balance sheet – Yahoo Finance - Yahoo Finance Singapore
Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million - Business Wire
Obsidian Therapeutics completes merger with Galera - Investing.com
Obsidian Therapeutics Completes Galera Merger and $350 Million Financing - citybiz
Obsidian Therapeutics completes merger with Galera By Investing.com - Investing.com India
Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create Publicly Listed Rare Disease Biotechnology Company to Advance Antisense Oligonucleotide Therapy Rugonersen for Angelman Syndrome - Yahoo Finance
Curis (CRIS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $CRIS - MarketBeat
Galera Flags Material Rights Change, But Details Remain a Mystery for Investors - finance.biggo.com
Halper Sadeh LLC is Investigating Whether LEG, AVNS, SEM, GRTX are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Obsidian Therapeutics to Present OBX-115 Phase 2 Clinical Data in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting - Business Wire
Obsidian, Galera to advance cell therapy following reverse merger - BioPharma Dive
Obsidian Therapeutics and Galera Therapeutics Enter $350 Million Merger Agreement - pharmexec.com
Obsidian and Galera reveal reverse merger plan - The Pharma Letter
Galera Therapeutics and Obsidian Therapeutics Announce - GlobeNewswire
GRTX Stock Alert: Halper Sadeh LLC is Investigating Whether Galera Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
enGene Therapeutics (Nasdaq:ENGN)Stock Analysis - Simply Wall Street
GALERA THERAPEUTICS (GRTX) Stock Price, News & Analysis - Stock Titan
Annual Financial Report07:00:05 30 Mar 2025RTW News article - London Stock Exchange
Iovance: The Company Makes It Hard To Estimate Revenue Growth (NASDAQ:IOVA) - Seeking Alpha
Obsidian Therapeutics Announces FDA Fast Track Designation for OBX-115 for the Treatment of Advanced Melanoma - Business Wire
Obsidian Therapeutics, Inc. Common Stock Stock (OBX) Financials Data
There is no financial data for Obsidian Therapeutics, Inc. Common Stock (OBX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):